147 related articles for article (PubMed ID: 34007563)
1. The Imaginary Worlds of Cure Proportion Modeling: Survivorship and Reference Case Pricing of Transformative Therapies.
Langley PC
Innov Pharm; 2019; 10(3):. PubMed ID: 34007563
[TBL] [Abstract][Full Text] [Related]
2. ICER, ISPOR AND QALYs: Tales of Imaginary Worlds.
Langley PC
Innov Pharm; 2019; 10(4):. PubMed ID: 34007578
[TBL] [Abstract][Full Text] [Related]
3. More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review's Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis.
Langley PC
Innov Pharm; 2020; 11(1):. PubMed ID: 34017631
[TBL] [Abstract][Full Text] [Related]
4. Nonsense on Stilts - Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds.
Langley PC
Innov Pharm; 2020; 11(1):. PubMed ID: 34017624
[TBL] [Abstract][Full Text] [Related]
5. More Unnecessary Imaginary Worlds - Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease.
Langley PC
Innov Pharm; 2020; 11(2):. PubMed ID: 34007618
[TBL] [Abstract][Full Text] [Related]
6. Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing Claims.
Langley PC
Innov Pharm; 2021; 12(1):. PubMed ID: 34007677
[TBL] [Abstract][Full Text] [Related]
7. Another Rush to Judgment: The Imaginary Worlds of ICER and Recommendations in Duchenne Muscular Dystrophy.
Langley PC
Innov Pharm; 2019; 10(3):. PubMed ID: 34007562
[TBL] [Abstract][Full Text] [Related]
8. Supping with the Devil: Belief and the Imaginary World of Multiple Myeloma Therapies Invented by the Institute for Clinical and Economic Review.
Langley PC
Innov Pharm; 2021; 12(3):. PubMed ID: 35601587
[TBL] [Abstract][Full Text] [Related]
9. Yet another Ersatz World: The ICER Final Evidence Report for Additive Cardiovascular Therapies.
Langley PC
Innov Pharm; 2019; 10(4):. PubMed ID: 34007580
[TBL] [Abstract][Full Text] [Related]
10. HTA and economics in the United States: a systematic review of ICER reports to evaluate trends, identify factors associated with recommendations, and understand implications.
Kruzikas DT; Malone DC; Pham S; Reinsch TK; Akehurst R
J Manag Care Spec Pharm; 2020 Dec; 26(12):1548-1557. PubMed ID: 33251996
[No Abstract] [Full Text] [Related]
11. The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER).
Langley PC
Innov Pharm; 2020; 11(3):. PubMed ID: 34007634
[TBL] [Abstract][Full Text] [Related]
12. More Unnecessary Imaginary Worlds - Part 3: Cystic Fibrosis and the Institute for Clinical and Economic Review's Draft Evidence Report.
Langley PC
Innov Pharm; 2020; 11(1):. PubMed ID: 34017638
[TBL] [Abstract][Full Text] [Related]
13. Alternative Facts and the ICER Proposed Policy on Access to Imaginary Pharmacoeconomic Worlds.
Langley PC
Innov Pharm; 2018; 9(2):1-5. PubMed ID: 34007702
[TBL] [Abstract][Full Text] [Related]
14. To Dream the Impossible Dream: The Commitment by the Institute for Clinical and Economic Review to Rewrite the Axioms of Fundamental Measurement for Hemophilia A and Bladder Cancer Value Claims.
Langley PC
Innov Pharm; 2020; 11(4):. PubMed ID: 34007652
[TBL] [Abstract][Full Text] [Related]
15. CVS Health and the Imaginary Worlds of the Institute for Clinical and Economic Review (ICER).
Langley PC
Innov Pharm; 2018; 9(4):. PubMed ID: 34007726
[TBL] [Abstract][Full Text] [Related]
16. Let a Thousand Models Bloom: ICER Analytics Opens the Floodgates to Cloud Pseudoscience.
Langley PC
Innov Pharm; 2021; 12(1):. PubMed ID: 34007666
[TBL] [Abstract][Full Text] [Related]
17. Do Research Groups Align on an Intervention's Value? Concordance of Cost-Effectiveness Findings Between the Institute for Clinical and Economic Review and Other Health System Stakeholders.
Sussman M; Yu JC; Menzin J
Appl Health Econ Health Policy; 2020 Aug; 18(4):477-489. PubMed ID: 31919779
[TBL] [Abstract][Full Text] [Related]
18. Post-Menopausal Quality of Life Claims: Overlooking the Requirements of Normal Science and Fundamental Measurement in ICER'S Cost-Effectiveness Assessment of Fezolinetant for Moderate to Severe Vasomotor Symptoms.
Langley PC
Innov Pharm; 2023; 14(1):. PubMed ID: 38035319
[TBL] [Abstract][Full Text] [Related]
19. The evolution of ICER's review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER's reports.
Ronquest NA; Paret K; Gould IG; Barnett CL; Mladsi DM
J Manag Care Spec Pharm; 2021 Nov; 27(11):1601-1612. PubMed ID: 34714108
[No Abstract] [Full Text] [Related]
20. More Unnecessary Imaginary Worlds - Part 2: The ICER Evidence Report on Modeling Oral Semaglutide for Type 2 Diabetes.
Langley PC
Innov Pharm; 2020; 11(1):. PubMed ID: 34017637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
